Publications by authors named "A Verschoor"

Introduction: Autoantibody-mediated complement activation plays an essential role in a variety of autoimmune disorders. However, the role of complement in systemic sclerosis (SSc) remains largely unknown. In this study, we aimed to determine the role of complement C3 in the development of a recently described SSc mouse model based on autoimmunity to angiotensin II receptor type 1 (AT1R).

View Article and Find Full Text PDF

Venous thromboembolism (VTE) is a common, deadly disease with an increasing incidence despite preventive efforts. Clinical observations have associated elevated antibody concentrations or antibody-based therapies with thrombotic events. However, how antibodies contribute to thrombosis is unknown.

View Article and Find Full Text PDF

Introduction: Treating older adults with chemotherapy remains a challenge, given their under-representation in clinical trials and the lack of robust treatment guidelines for this population. Moreover, older patients, especially those with frailty, have an increased risk of developing chemotherapy-related toxicity, resulting in a decreased quality of life (QoL), increased hospitalisations and high healthcare costs. Phase II trials have suggested that upfront dose reduction of chemotherapy can reduce toxicity rates while maintaining efficacy, leading to fewer treatment discontinuations and an improved QoL.

View Article and Find Full Text PDF

The transition from linear production towards a circular agro-food system is an important step towards increasing Europe's sustainability. This requires re-designing the food production systems, which inevitably comes with challenges as regards controlling the safety of our food, animals and the ecosystem. Where in current food production systems many food safety hazards are understood and well-managed, it is anticipated that with the transition towards circular food production systems, known hazards may re-emerge and new hazards will appear or accumulate, leading to new -and less understood- food safety risks.

View Article and Find Full Text PDF
Article Synopsis
  • Complement-mediated diseases can be treated using specific inhibitors, but traditional systemic approaches may increase infection risk and have limited efficacy due to high levels of complement in circulation.
  • Researchers developed a new therapy, an antibody fusion protein (C3d-mAb-2fH), that targets complement activity directly in affected tissues rather than systemic circulation, improving localized treatment.
  • Experiments show that this approach effectively inhibits complement in tissue and has demonstrated positive results in models for skin and kidney diseases without causing systemic side effects.
View Article and Find Full Text PDF